26 July 2024
EMA/273861/2024
EMEA/H/C/005737

Public statement

Jcovden[1] (COVID-19 Vaccine Janssen (Ad26.COV2.S))

Withdrawal of the marketing authorisation in the European Union

On 26 July 2024, the European Commission withdrew the marketing authorisation for Jcovden (COVID-19 Vaccine Janssen (Ad26.COV2.S)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Janssen-Cilag International N.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Jcovden was granted conditional marketing authorisation in the EU on 11 March 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorisation, valid for 5 years, on 09 January 2023.

The European Public Assessment Report (EPAR) for Jcovden will be updated to indicate that the marketing authorisation is no longer valid.

[1] Previously known as COVID-19 Vaccine Janssen

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union